Deal Watch: Zymeworks Adds Daiichi To List Of Partners In I-O Cross Collaboration

Amgen gets into RNAi for cardiovascular indications with Arrowhead deal. Lilly and J&J out-license preclinical candidates, for epilepsy and cancer respectively, to smaller firms Cerecor and Tracon.

chart

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy transactions that occurred between Sept.23-30. Deal Watch is supported by deal intelligence from Strategic Transactions.

Canadian biotech Zymeworks Inc. and Japan's Daiichi Sankyo Co. Ltd. announced a cross-cutting cancer alliance Sept. 28 that will focus on immuno-oncology

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business